Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease

Diabetes Obes Metab. 2023 May;25(5):1398-1402. doi: 10.1111/dom.14965. Epub 2023 Feb 14.

Authors

Affiliations

¹ Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
² Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, New York, USA.
³ University of Tennessee Health Science Center, Memphis, Tennessee, USA.
⁴ University of Toronto, Toronto, Ontario, Canada.
⁵ Unit of Cardiology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.
⁶ University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, Texas, USA.
⁷ AdventHealth Translational Research Institute, Orlando, Florida, USA.
⁸ Merck & Co., Inc, Rahway, New Jersey, USA.
⁹ Pfizer Inc, New York, New York, USA.
¹⁰ Pfizer Inc, Groton, Connecticut, USA.

PMID: 36594154
DOI: 10.1111/dom.14965

No abstract available

Keywords: REDUCE-IT; VERTIS CV; cardiovascular risk reduction; icosapent ethyl; type 2 diabetes.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Atherosclerosis* / complications
Atherosclerosis* / drug therapy
Atherosclerosis* / prevention & control
Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / prevention & control
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Eicosapentaenoic Acid
Heart Disease Risk Factors
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Hypertriglyceridemia*
Risk Factors

Substances

eicosapentaenoic acid ethyl ester
Eicosapentaenoic Acid
Hydroxymethylglutaryl-CoA Reductase Inhibitors